KPTI earnings call for the period ending June 30, 2020.
News & Analysis: Karyopharm Therapeutics
Shares jump after the biopharma receives some praise from Wall Street.
Traders cheer after the company reports a regulatory win.
Investors were pleased with the company's latest presentation.
An FDA delay was seen as good news for the drugmaker.
It looks like an upcoming FDA advisory committee meeting will be an uncomfortable affair for this clinical-stage biotech.
This clinical-stage company reported significant news yesterday.
It was an exciting month of ups and downs for the biotech and its blood-cancer candidate.
Shares dropped after the biotech reported news from an important phase 2 clinical trial.
An approval ahead of key trial data is sparking investor's enthusiasm.